Therapeutic window for nicotinamide following transient focal cerebral ischemia.
The therapeutic window with the neuroprotectant nicotinamide (NAm) was tested in a model of stroke. Either 2, 4 or 6 h after the onset of transient (2 h) focal cerebral ischemia, Wistar rats received either saline or NAm (500 mg/kg). Sensory and motor behavioral scores and weight of the animals were obtained before surgery, and 2 h, 3 and 7 days after stroke onset. Cerebral infarct volumes were measured on day 7 after sacrifice. NAm given 4 or 6 h after stroke onset significantly (p<0.05) reduced the cerebral infarction and improved the behavioral scores, respectively, compared to saline-injected animals. There was a non-significant improvement in weight gained by NAm-treated rats at 3 and 7 days following stroke compared to the saline-injected controls.
Ayoub
Issam A
IA
Neurophysiology Laboratory, Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Maynard
Kenneth I
KI
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002544:Cerebral Infarction / Q000473:pathology; D004334:Drug Administration Schedule; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D008297:Male; D009420:Nervous System / Q000187:drug effects / Q000503:physiopathology; D009536:Niacinamide / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D015430:Weight Gain / Q000187:drug effects
D009536:Niacinamide